Questions to Ask when Considering a Lymphoma Clinical Trial
Who can participate in this trial?
What are the eligibility requirements?
How do the potential benefits compare to other treatment options?
What are the trial’s tests and treatments?
How long will the trial last?
How will the trial and its possible side effects affect my daily life?
Are there treatments to help alleviate side effects?
Will my insurance company cover my costs?
Who will monitor my care and safety?
Who will review the information collected during the trial?
Will I be hospitalized? If so, how often and for how long?
Will I be able to see my own doctor? Who will be in charge of my care?
How often will I need to visit a physician’s office?
What support will be available for me and my caregivers during the trial? Can I talk to other people in the trial?
What is the long-term follow-up care?
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
